Visikol, a North Brunswick, NJ-based drug discovery service company, secured new round of funding of undisclosed amount.
Backers included pharma services industry executives Brian Mulhall and Alan Weiss.
The company intends to use the funds to develop bio-imaging services for drug discovery such as 3D In Vitro cell culture assays as well as expand the its commercial operations.
Led by CEO Dr. Michael Johnson and COO Nick Crider, Visikol is focused on accelerating drug discovery through quantitative histopathology and using their patented Visikol® HISTO™ tissue clearing technology to transform tissues into three dimensional data sets that can be mined for actionable insights. When paired with fluorescent labeling and 3D microscopy, Visikol® HISTO™ allows tissues such as 3D cell culture models or whole tissues to be imaged in their entirety in 3D.